209 results on '"Keating, Karen"'
Search Results
2. Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma
3. TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
4. The role of the estimand framework in the analysis of patient-reported outcomes in single-arm trials: a case study in oncology.
5. Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project
6. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
7. Does recall period matter? Comparing PROMIS ® physical function with no recall, 24-hr recall, and 7-day recall
8. Patient-level Factors Associated With the Initial Management of Older Adults Diagnosed With Follicular Lymphoma: A Surveillance, Epidemiology, and End Results–Medicare Analysis
9. Survival benefit associated with treating follicular lymphoma in patients 80 years or older
10. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)
11. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers
12. Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures
13. Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice
14. Development of a Joint Commission Disease-Specific Care Certification Program for Parkinson Disease in an Acute Care Hospital
15. Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)
16. What’s in a word? Defining “gene therapy medicines”
17. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
18. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials.
19. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
20. Effect of COVID-19 Pandemic Control Measures on Diagnoses of Hematologic Cancer Among CMS Population in 2020
21. Abstract 152: A machine learning approach to detect FFPE artefacts leads to accurate estimation of tumor mutational burden from sequencing data without a matched normal
22. Abstract 394: Prognosis and molecular characteristics of patients with TRK fusion cancer in the 100,000 Genomes Project
23. sj-pdf-1-tam-10.1177_1758835920975613 – Supplemental material for A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors
24. Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer: An expanded dataset.
25. sj-pdf-1-tam-10.1177_1758835920975613 – Supplemental material for A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors
26. Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer:An intra-patient comparative analysis
27. Fluoroquinolone Therapy for Uncomplicated Skin and Skin Structure Infections: A Retrospective Database Comparison of Treatment Duration, Failures and Charges
28. Survey of Symptom Burden in Women with Uncomplicated Urinary Tract Infections
29. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies
30. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis
31. 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update
32. Abstract 09: Cancers with NTRK gene fusions: Molecular characteristics and prognosis
33. Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.
34. Growth modulation index (GMI) as a comparative efficacy measure of larotrectinib versus prior systemic treatments for TRK fusion cancer patients.
35. Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-Medicare analysis of elderly patients
36. A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors
37. Economic burden of uncomplicated urinary tract infections: direct, indirect and intangible costs
38. Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire
39. A 'gap' between physician and patient assessment of symptom severity in acute cystitis? A multicenter trial of women treated with extended-release ciprofloxacin
40. Educating patients with uncomplicated UTIs: the effect of an educational brochure on patient knowledge
41. Is there an ocean of difference? A comparison of the European Community's and United States' environmental regulations protecting air and water quality.
42. Does recall period matter? Comparing PROMIS® physical function with no recall, 24-hr recall, and 7-day recall
43. Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data
44. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib.
45. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.
46. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies.
47. Validation of a patient-administered questionnaire to measure the activity impairment experienced by women with uncomplicated urinary tract infection: the Activity Impairment Assessment (AIA)
48. Does recall period matter? Comparing PROMIS® physical function with no recall, 24-hr recall, and 7-day recall.
49. Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data.
50. Patient-reported outcomes from a phase 2 study of copanlisib in patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma (iNHL).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.